- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Toshiba takes aim at CT radiation
In the battle against patient overdose, Toshiba America Medical Systems brought two weapons to RSNA 2010. One is its Adaptive Iterative Dose Reduction (AIDR), software similar in approach to products from competing CT vendors who use iterative reconstruction to squeeze noise out of their images. The other, Target CTA, is a dose protocol devised specifically for cardiac scans done on the Aquilion One.
In the battle against patient overdose, Toshiba America Medical Systems brought two weapons to RSNA 2010. One is its Adaptive Iterative Dose Reduction (AIDR), software similar in approach to products from competing CT vendors who use iterative reconstruction to squeeze noise out of their images. The other, Target CTA, is a dose protocol devised specifically for cardiac scans done on the Aquilion One.
AIDR made a cameo appearance at the RSNA meeting last year, when it was discussed but not described at any length. It has recently received 510(k) clearance from the FDA and Toshiba is claiming AIDR can achieve dose reductions of as much as 75%.
The new cardiac dose protocol, Target CTA, is a commercial product but designed for use only on patients, including pediatric ones, with stable heart rates. The protocol tailors exposure, which on the Aquilion One is accomplished in a single rotation of the gantry, thanks to the onboard 16-cm-wide detector.
With Target CTA, operators more accurately target the heart, according to Toshiba and, thereby, minimize padding of the scan range that leads to increased patient dose. Used with Toshiba’s advanced SURECardio Prospective, which can reduce radiation dose by up to 80%, Target CTA can lower radiation by another 20%, according to the company.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.
